NCT04743791View on ClinicalTrials.gov

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

September 30, 2026

Conditions
Asthma
Interventions
DRUG

Dupilumab

Dupilumab is supplied as a sterile aqueous solution for SC injection at the concentration of 175 mg/mL in glass pre-filled syringe to deliver 200 mg in 1.14mL.

OTHER

Placebo

Sterile placebo for dupilumab will be provided in identically matched glass pre-filled syringe to deliver 200 mg in 1.14mL, which will match dupilumab 200 mg (1.14mL).

Trial Locations (1)

15213

RECRUITING

The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh

All Listed Sponsors
lead

Sally E. Wenzel MD

OTHER